Mycobacterium Abscessus Pulmonary Disease (MAPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Mycobacterium Abscessus Pulmonary Disease (MAPD) Market Outlook

Thelansis’s “Mycobacterium Abscessus Pulmonary Disease (MAPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Mycobacterium Abscessus Pulmonary Disease (MAPD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Mycobacterium Abscessus Pulmonary Disease (MAPD) Overview

Mycobacterium abscessus pulmonary disease (MAPD) is a severe lung infection caused by M. abscessus, a rapidly growing nontuberculous mycobacterium that is highly resistant to many antibiotics. It most often affects individuals with underlying structural lung disorders such as cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease, and presents with persistent cough, sputum production, fatigue, weight loss, and sometimes hemoptysis. Diagnosis requires microbiological confirmation through culture and molecular testing to identify subspecies and drug resistance, as clinical and radiographic features can overlap with other chronic lung infections. Treatment is complex and prolonged, typically involving multidrug regimens that combine macrolides with intravenous agents such as amikacin, imipenem, or tigecycline, yet outcomes remain poor due to frequent relapse and limited drug efficacy. Because of its multidrug resistance, clinical severity, and impact on vulnerable patient populations, MAPD is considered one of the most challenging nontuberculous mycobacterial diseases to manage, driving ongoing research into novel antimicrobials and host‑directed therapies.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Mycobacterium Abscessus Pulmonary Disease (MAPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035